Man Group’s Karyopharm Therapeutics KPTI Stock Holding History

Man Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	–	–	1834
2022 Q2	–	Sell	-1,018	Closed	-$93.4K	–	1925
2022 Q1	$113K	Buy	+1,018	New	+$127K	﹤0.01%	2038
2021 Q2	–	Sell	-776	Closed	-$122K	–	2028
2021 Q1	$122K	Sell	776 -3,976	-84%	-$838K	﹤0.01%	1788
2020 Q4	$1.1M	Buy	4,752 +43	+0.9%	+$9.96K	﹤0.01%	1387
2020 Q3	$1.03M	Buy	+4,709	New	+$1.15M	﹤0.01%	1364
2020 Q1	–	Sell	-1,320	Closed	-$380K	–	1746
2019 Q4	$380K	Sell	1,320 -80	-6%	-$17.4K	﹤0.01%	1634
2019 Q3	$202K	Buy	+1,400	New	+$190K	﹤0.01%	1709
2019 Q1	–	Sell	-1,227	Closed	-$172K	–	2019
2018 Q4	$172K	Buy	+1,227	New	+$207K	﹤0.01%	1820

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Man Group's KPTI Position: Q1 2023 in Review

Man Group held its Karyopharm Therapeutics (KPTI) position steady in Q1 2023 at 0 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Man Group first reported a position in KPTI in Q4 2018 and has held it in 7 quarters since. The position peaked at $1.1M in Q4 2020. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Man Group held 0 shares of Karyopharm Therapeutics worth $173K as of Q1 2023.
Man Group left its Karyopharm Therapeutics share count unchanged in Q1 2023.
Karyopharm Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2023, its #1834 holding.
Man Group first reported a position in Karyopharm Therapeutics in Q4 2018 and has held it in 7 quarters since.
Man Group's Karyopharm Therapeutics position peaked at $1.1M in Q4 2020.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.